[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 26 of about 26
1. Horiguchi K, Yamada M, Umezawa R, Satoh T, Hashimoto K, Tosaka M, Yamada S, Mori M: Somatostatin receptor subtypes mRNA in TSH-secreting pituitary adenomas: a case showing a dramatic reduction in tumor size during short octreotide treatment. Endocr J; 2007 Jun;54(3):371-8
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatostatin receptor subtypes mRNA in TSH-secreting pituitary adenomas: a case showing a dramatic reduction in tumor size during short octreotide treatment.
  • TSH-secreting adenoma is a rare pituitary adenoma, and the expression levels of the specific subtypes of somatostatin receptors (sstr) mRNAs have remained obscure.
  • To determine the quantitative expression of the sstr1-5 mRNAs in TSH-secreting adenomas that may be related to the efficacy of treatment with a somatostatin analogue, expression of the sstr1-5 mRNAs was examined and compared in TSH-secreting adenomas and other pituitary adenomas.
  • The pituitary adenomas were obtained at transsphenoidal surgery from 4 cases of TSH-secreting adenoma, including 1 patient showing a significant shrinkage of the tumor size after only 10 days of octreotide treatment, 2 patients without tumor size reduction and 1 patient without treatment, and 5 GH-secreting adenomas, 6 prolactinomas, 5 nonfunctioning adenomas, 4 ACTH-secreting adenomas and normal pituitaries at autopsy from 4 normal subjects.
  • In comparison to the normal pituitary, sstr2A>sstr1>sstr5>sstr3 mRNAs were expressed in the TSH-secreting adenomas examined.
  • The expression level of sstr2 mRNA was significantly higher than those in normal pituitary, prolactinomas, ACTH-secreting and nonfunctioning pituitary adenomas.
  • The patient with marked shrinkage of the tumor showed the highest expression of both sstr2 and sstr5 mRNAs among all the cases of pituitary adenoma.
  • A TSH-secreting tumor without shrinkage showed a similar expression level of sstr2 mRNA.
  • These findings demonstrated that TSH-secreting adenomas express sstr1, 2A, 3 and 5 mRNAs, predominantly sstr2A, and in addition to the expression of sstr2 mRNA, the expression level of sstr5 mRNA may be a factor affecting the tumor shrinkage by somatostatin analogues against TSH-secreting adenomas.
  • [MeSH-major] Adenoma / drug therapy. Adenoma / genetics. Octreotide / therapeutic use. Pituitary Neoplasms / drug therapy. Pituitary Neoplasms / genetics. Receptors, Somatostatin / genetics. Thyrotrophs / pathology. Tumor Burden / drug effects
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents, Hormonal / therapeutic use. Female. Gene Expression Regulation, Neoplastic / drug effects. Humans. Male. Middle Aged. Protein Isoforms / genetics. Protein Isoforms / metabolism. RNA, Messenger / metabolism. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17420609.001).
  • [ISSN] 0918-8959
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Protein Isoforms; 0 / RNA, Messenger; 0 / Receptors, Somatostatin; RWM8CCW8GP / Octreotide
  •  go-up   go-down


2. Yoshihara A, Isozaki O, Hizuka N, Nozoe Y, Harada C, Ono M, Kawamata T, Kubo O, Hori T, Takano K: Expression of type 5 somatostatin receptor in TSH-secreting pituitary adenomas: a possible marker for predicting long-term response to octreotide therapy. Endocr J; 2007 Feb;54(1):133-8
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of type 5 somatostatin receptor in TSH-secreting pituitary adenomas: a possible marker for predicting long-term response to octreotide therapy.
  • In TSH-secreting pituitary adenomas (TSHoma), octreotide (OCT) therapy reduces tumor size and TSH secretion in some cases but not in others.
  • As OCT acts through various types of somatostatin receptors (SSTRs), the different responses of TSHoma to OCT might be explained by the differences of SSTR expression.
  • We therefore studied the expression of subtype-specific SSTR mRNA transcripts in tumor tissues by RT-PCR.
  • Type 2 (SSTR2) mRNA transcripts were detected in all 8 tumors but those of SSTR3 and SSTR5 were demonstrated only in 5 of them.
  • Serum TSH levels were decreased by OCT administration test in all patients but OCT therapy was effective in two patients out of three.
  • These observations suggest that the temporal decrease of TSH by OCT may be mediated by SSTR2, and that the long term response to OCT therapy may be related with the expression of SSTR5.
  • Therefore, the expression of SSTR5 in TSHoma may be a useful marker for predicting the outcome of the therapy, but further studies with larger numbers of patients are necessary.
  • [MeSH-major] Adenoma / drug therapy. Adenoma / genetics. Biomarkers, Tumor / genetics. Octreotide / therapeutic use. Pituitary Neoplasms / drug therapy. Pituitary Neoplasms / genetics. Receptors, Somatostatin / genetics. Thyrotropin / secretion
  • [MeSH-minor] Antineoplastic Agents, Hormonal / therapeutic use. Female. Gene Expression Regulation, Neoplastic / drug effects. Humans. Male. Prognosis. Protein Isoforms / genetics. Time. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17159301.001).
  • [ISSN] 0918-8959
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 0 / Protein Isoforms; 0 / Receptors, Somatostatin; 0 / somatostatin receptor 5; 9002-71-5 / Thyrotropin; RWM8CCW8GP / Octreotide
  •  go-up   go-down


3. Prieto-Tenreiro A, Díaz-Guardiola P: Long term treatment of a thyrotropin-secreting microadenoma with somatostatin analogues. Arq Bras Endocrinol Metabol; 2010;54(5):502-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long term treatment of a thyrotropin-secreting microadenoma with somatostatin analogues.
  • Thyrotropin (TSH) secreting pituitary adenomas (TSH-omas) account for < 1% of all pituitary adenomas and are a rare cause of hyperthyroidism.
  • The diagnosis is often made at the stage of macroadenoma because of the aggressive nature of the tumor and due to the fact that patients are mistakenly treated for more common primary hyperthyroidism for a long time.
  • First line therapy is transsphenoidal resection of the tumor, which can cure one-third of the patients completely.
  • As transsphenoidal surgery was not considered effective, medical therapy with a somatostatin analogue was initiated.
  • Currently, at four years of follow-up, the patient continues on this treatment and remains euthyroid and asymptomatic.
  • We report a case of successful long-term treatment with SSA, after unsuccessful surgery.
  • [MeSH-major] Adenoma / drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Peptides, Cyclic / therapeutic use. Pituitary Neoplasms / drug therapy. Somatostatin / analogs & derivatives. Thyrotropin / secretion

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20694413.001).
  • [ISSN] 1677-9487
  • [Journal-full-title] Arquivos brasileiros de endocrinologia e metabologia
  • [ISO-abbreviation] Arq Bras Endocrinol Metabol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Peptides, Cyclic; 118992-92-0 / lanreotide; 51110-01-1 / Somatostatin; 9002-71-5 / Thyrotropin
  •  go-up   go-down


Advertisement
4. Chen S, Li M, Lian XL, Zeng ZP, Dai WX, Li F, Yu W, Wang RZ: [Octreotide in the diagnosis and treatment of pituitary thyrotropin-secreting adenoma]. Zhonghua Nei Ke Za Zhi; 2006 Nov;45(11):910-3
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Octreotide in the diagnosis and treatment of pituitary thyrotropin-secreting adenoma].
  • OBJECTIVE: To evaluate the efficacy of octreotide in the diagnosis and treatment of pituitary thyrotropin (TSH)-secreting adenoma.
  • METHODS: A 34-year man presented with central hyperthyroidism and pituitary TSH-secreting macroadenoma was reported. (99 m)Tc-octreotide scan and magnetic resonance imaging were completed to make the location diagnosis of the adenoma.
  • Serum TSH level and tumor size were observed and trans-sphenoidal adenoma resection was completed.
  • RESULTS: Pituitary TSH-secreting adenoma displayed positive sign in (99 m)Tc-octreotide scan.
  • Antithyroid drug was of no help in depressing thyroid function to normal.
  • However, octreotide treatment could revert thyroid function to normal rapidly.
  • CONCLUSIONS: (99 m)Tc-octreotide scan is one of the useful tools for location diagnosis of TSH-secreting adenoma.
  • Octreotide can effectively control central hyperthyroid and make tumor shrink, and it can be a satisfactory method of preoperative preparation for TSH-secreting adenoma.
  • [MeSH-major] Adenoma / drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Octreotide / analogs & derivatives. Octreotide / therapeutic use. Organotechnetium Compounds. Pituitary Neoplasms / drug therapy. Thyrotropin / secretion

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17313878.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / 99mTc-octreotide; 0 / Antineoplastic Agents, Hormonal; 0 / Organotechnetium Compounds; 9002-71-5 / Thyrotropin; RWM8CCW8GP / Octreotide
  •  go-up   go-down


5. Del Monte P, Bernasconi D, Ruelle A, Marugo A, Marugo M, Torre R: [Effect of long-term treatment with octreotide-lar in a TSH-secreting pituitary macroadenoma and secondary hyperthyroidism]. Minerva Endocrinol; 2005 Jun;30(2):95-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of long-term treatment with octreotide-lar in a TSH-secreting pituitary macroadenoma and secondary hyperthyroidism].
  • [Transliterated title] Effetto del trattamento a lungo termine con octreotide-Lar in un caso di macroadenoma ipofisario TSH-secernente.
  • Thyroid function evaluation showed secondary hyperthyroidism, with high free thyroid hormone levels and TSH inappropriately in the high-normal range (4.2 mU/ml), only slightly responsive to TRH-stimulation (6 microU/ml).
  • The patient underwent transphenoidal adenomectomy, and immunohistochemistry confirmed the diagnosis of a TSH-secreting pituitary macroadenoma.
  • The patient was treated with octreotide-Lar (20 mg/monthly), which normalized FT3, FT4 and TSH levels already after 3 months of therapy.
  • This effect is still maintained at 42 months of treatment.
  • MR imaging showed a reduction in the residual lesion after 18 months (>50% in comparison with postsurgical MR) and a further decrease after 36 months of treatment).
  • This suggests that the antiproliferative effect on the adenomatous cells is progressive and continues over time.
  • This patients did not receive radiotherapy, so this action is entirely due to the medical treatment.
  • No significant side effects developed and the patient's compliance was good.
  • [MeSH-major] Adenoma / drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Hyperthyroidism / drug therapy. Hyperthyroidism / etiology. Octreotide / therapeutic use. Pituitary Neoplasms / drug therapy. Thyrotropin / secretion
  • [MeSH-minor] Aged. Humans. Male. Thyroid Hormones / blood. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hyperthyroidism.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15988405.001).
  • [ISSN] 0391-1977
  • [Journal-full-title] Minerva endocrinologica
  • [ISO-abbreviation] Minerva Endocrinol.
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Thyroid Hormones; 9002-71-5 / Thyrotropin; RWM8CCW8GP / Octreotide
  •  go-up   go-down


6. Mouton F, Faivre-Defrance F, Cortet-Rudelli C, Assaker R, Soto-Ares G, Defoort-Dhellemmes S, Blond S, Wemeau JL, Vantyghem MC: TSH-secreting adenoma improved with cabergoline. Ann Endocrinol (Paris); 2008 Jun;69(3):244-8
Hazardous Substances Data Bank. LIOTHYRONINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TSH-secreting adenoma improved with cabergoline.
  • TSH-secreting adenomas are rare tumors, representing only 0.5 to 2.5% of pituitary adenomas.
  • Biologically, free T4 and T3 serum levels are elevated, contrasting with inadequate serum TSH levels and increased alpha chains.
  • Treatment is based on surgery, possibly associated with somatostatin analogs and radiotherapy.
  • We suggest that cabergoline should be considered as an alternative treatment in cases of pituitary adenomas that resist traditional treatments.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Ergolines / therapeutic use. Pituitary Neoplasms / drug therapy. Pituitary Neoplasms / secretion. Thyrotropin / secretion

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18486933.001).
  • [ISSN] 0003-4266
  • [Journal-full-title] Annales d'endocrinologie
  • [ISO-abbreviation] Ann. Endocrinol. (Paris)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Ergolines; 06LU7C9H1V / Triiodothyronine; 9002-71-5 / Thyrotropin; LL60K9J05T / cabergoline; Q51BO43MG4 / Thyroxine
  •  go-up   go-down


7. Park C, Yang I, Woo J, Kim S, Kim J, Kim Y, Sohn S, Kim E, Lee M, Park H, Jung J, Park S: Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: the relationship with endogenous srif activity and response to octreotide. Endocr J; 2004 Apr;51(2):227-36
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: the relationship with endogenous srif activity and response to octreotide.
  • To investigate the potential pathophysiologic role of human SRIF receptor gene expression in GH-secreting adenomas in acromegalic patients, we studied the relationship between the SRIF receptor gene expression, endogenous SRIF activity and exogenous response to octreotide in 16 acromagalic patients.
  • Hypothalamic somatostatinergic activity (HSA) was assessed by glucose-induced suppression of TRH-stimulated TSH secretion.
  • Pituitary tumor SRIF receptor subtype 2 and 5 (sst2 and sst5) mRNA levels were measured by real-time RT-PCR.
  • These results suggest common transcriptional and/or post-transcriptonal regulatory mechanisms for these SRIF receptor subtypes within GH-secreting pituitary adenomas.
  • The functional observations suggest that the degree (or level) of sst2 and sst5 expression is critical for the ultimate GH response of somatotropinomas to endogenous SRIF tone and exogenous SRIF analogue therapy.
  • [MeSH-major] Adenoma / drug therapy. Adenoma / metabolism. Antineoplastic Agents, Hormonal / therapeutic use. Octreotide / therapeutic use. Pituitary Neoplasms / drug therapy. Pituitary Neoplasms / metabolism. Receptors, Somatostatin / metabolism
  • [MeSH-minor] Acromegaly / drug therapy. Adult. Female. Gene Expression. Human Growth Hormone / secretion. Humans. Male. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15118275.001).
  • [ISSN] 0918-8959
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Receptors, Somatostatin; 0 / somatostatin receptor 2; 0 / somatostatin receptor 5; 12629-01-5 / Human Growth Hormone; RWM8CCW8GP / Octreotide
  •  go-up   go-down


8. Colao A, Filippella M, Pivonello R, Di Somma C, Faggiano A, Lombardi G: Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours. Eur J Endocrinol; 2007 Apr;156 Suppl 1:S57-63
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours.
  • Medical treatment with somatostatin analogues is a cornerstone of GH- and TSH-secreting tumours, while treatment with dopamine agonists is a cornerstone of prolactin-secreting tumours.
  • Dopamine agonists have also demonstrated some efficacy in patients with GH- and TSH-secreting adenomas.
  • Neither ACTH-secreting nor clinically non-functioning tumours have a well-established medical treatment.
  • Combination treatment with both somatostatin analogues and dopamine agonists has been poorly investigated.
  • Some studies conducted in small series have documented an additive effect of both drugs in patients with GH-secreting adenomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Eur J Endocrinol. 2007 Oct;157(4):543
  • (PMID = 17413190.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dopamine Agonists; 0 / Receptors, Dopamine; 0 / Receptors, Somatostatin; 51110-01-1 / Somatostatin
  • [Number-of-references] 59
  •  go-up   go-down


9. Koch CA, Skarulis MC, Patronas NJ, Sarlis NJ: [TSH-secreting pituitary adenoma: 16 years follow-up]. Med Klin (Munich); 2000 Jan 15;95(1):49-50
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [TSH-secreting pituitary adenoma: 16 years follow-up].
  • [Transliterated title] TSH-sezernierendes Hypophysenadenom: 16 Jahre Follow-up (TSH-secreting pituitary adenoma).
  • [MeSH-major] Adenoma / secretion. Pituitary Neoplasms / secretion. Thyrotropin / biosynthesis
  • [MeSH-minor] Aged. Antineoplastic Agents, Hormonal / therapeutic use. Follow-Up Studies. Humans. Hypophysectomy. Male. Neoplasm, Residual / drug therapy. Neoplasm, Residual / surgery. Octreotide / therapeutic use. Pituitary Hormones / blood. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10668345.001).
  • [ISSN] 0723-5003
  • [Journal-full-title] Medizinische Klinik (Munich, Germany : 1983)
  • [ISO-abbreviation] Med. Klin. (Munich)
  • [Language] ger
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Pituitary Hormones; 9002-71-5 / Thyrotropin; RWM8CCW8GP / Octreotide
  •  go-up   go-down


10. Alves C, Alves AC: Primary hypothyroidism in a child simulating a prolactin-secreting adenoma. Childs Nerv Syst; 2008 Dec;24(12):1505-8
Hazardous Substances Data Bank. LEVOTHYROXINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary hypothyroidism in a child simulating a prolactin-secreting adenoma.
  • OBJECTS: To report a case of primary hypothyroidism associated to hyperprolactinemia mimicking a prolactin secreting adenoma.
  • Diagnostic evaluation demonstrated free thyroxine (F-T4): 0.22 ng/dL (0.75-1.80) and thyroid-stimulating hormone (TSH): 135 UI/mL (0.3-5.0).
  • Due to the possibility of a pseudoprolactinoma caused by hyperplasia of the TSH and prolactin-producing cells, she was treated for the primary hypothyroidism with levothyroxine.
  • After 2 months, F-T4, TSH, and prolactin returned to normal values.
  • [MeSH-major] Adenoma / diagnosis. Hypothyroidism / diagnosis. Pituitary Neoplasms / diagnosis. Prolactin / secretion
  • [MeSH-minor] Child. Diagnosis, Differential. Female. Humans. Hyperprolactinemia / blood. Hyperprolactinemia / drug therapy. Magnetic Resonance Imaging. Thyroxine / administration & dosage. Thyroxine / therapeutic use

  • MedlinePlus Health Information. consumer health - Hypothyroidism.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Reprod Med. 2002 Nov;20(4):365-74 [12536359.001]
  • [Cites] CMAJ. 2003 Sep 16;169(6):575-81 [12975226.001]
  • [Cites] Fertil Steril. 2005 Jul;84(1):181-5 [16009175.001]
  • [Cites] Horm Res. 2005;63(2):61-4 [15668525.001]
  • [Cites] Eur Radiol. 2000;10(3):516-8 [10757007.001]
  • [Cites] Intern Med. 2001 Aug;40(8):751-5 [11518117.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Mar;82(3):808-11 [9062487.001]
  • [Cites] Treat Endocrinol. 2003;2(1):23-32 [15871552.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Jan;80(1):276-9 [7829625.001]
  • [Cites] Pediatr Neurosurg. 1998 Apr;28(4):195-7 [9732247.001]
  • [Cites] Endocrinol Metab Clin North Am. 2001 Sep;30(3):585-610 [11571932.001]
  • [Cites] Arq Bras Endocrinol Metabol. 2004 Jun;48(3):423-6 [15640908.001]
  • [Cites] Australas Radiol. 1999 Feb;43(1):121-3 [10901888.001]
  • [Cites] Pediatr Neurol. 1994 Mar;10(2):166-8 [8024669.001]
  • [Cites] J Pediatr Endocrinol Metab. 2001 Nov-Dec;14(9):1665-9 [11795659.001]
  • [Cites] Nat Rev Cancer. 2002 Nov;2(11):836-49 [12415254.001]
  • [Cites] Indian Pediatr. 2001 Apr;38(4):432-3 [11313523.001]
  • [Cites] JAMA. 1989 Dec 8;262(22):3175-7 [2810675.001]
  • [Cites] Br J Neurosurg. 1990;4(2):107-12 [2357279.001]
  • [Cites] Arq Bras Endocrinol Metabol. 2005 Jun;49(3):468-72 [16544004.001]
  • [Cites] Clin Endocrinol (Oxf). 2003 Feb;58(2):185-91 [12580934.001]
  • (PMID = 18690463.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 9002-62-4 / Prolactin; Q51BO43MG4 / Thyroxine
  •  go-up   go-down


11. Erem C, Hacihasanoglu A, Sari A, Onder Ersöz H, Ukinç K, Fidan S: A rare case and a rapid tumor response to therapy: dramatic reduction in tumor size during octreotide treatment in a patient with TSH-secreting pituitary macroadenoma. Endocrine; 2004 Nov;25(2):141-5
Hazardous Substances Data Bank. LEVOTHYROXINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case and a rapid tumor response to therapy: dramatic reduction in tumor size during octreotide treatment in a patient with TSH-secreting pituitary macroadenoma.
  • Thyrotropin (TSH)-secreting pituitary adenomas are the less frequent form of presentation of pituitary tumors.
  • The presence of somatostatin receptors on TSH-secreting adenomas allows treatment of central hyperthyroidism with somatostatin analogs.
  • We report a 21-yr-old woman with TSH-secreting pituitary macroadenoma, who was diagnosed based on the symptoms of hyperthyroidism, the lack of inhibition of serum TSH despite an increased serum free thyroxine (FT4), a low response of serum TSH to thyrotropin-releasing hormone, and a pituitary tumor as revealed by magnetic resonance imaging.
  • The treatment with the somatostatin analog octreotid resulted in inhibition of serum TSH and FT4 to euthyroid levels with concomitant clinical improvements such as the disappearance of sweating, tachycardia, and finger tremors within 7 d.
  • The tumor size diminished dramatically within 6 wk during treatment of one monthly im injection of 20 mg octreotide-LAR.
  • These effects were continued over 2 yr after the start of octreotide-LAR therapy.
  • Therefore, octreotide-LAR appears to be a useful therapeutic tool to facilitate the medical treatment of TSH-secreting pituitary tumors.
  • [MeSH-major] Adenoma / drug therapy. Antineoplastic Agents, Hormonal / administration & dosage. Octreotide / administration & dosage. Thyroid Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 1976 Oct;43(4):924-7 [824303.001]
  • [Cites] Clin Endocrinol (Oxf). 1987 Apr;26(4):395-405 [2888549.001]
  • [Cites] Ann Intern Med. 1993 Aug 1;119(3):236-40 [8323093.001]
  • [Cites] Przegl Lek. 2003;60(11):768-71 [15058054.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Aug;75(2):540-6 [1353505.001]
  • [Cites] Eur J Endocrinol. 1999 Jun;140(6):528-37 [10366409.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Jul;79(1):113-8 [8027215.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Apr 17;209(2):400-6 [7733906.001]
  • [Cites] N Engl J Med. 1987 Jul 2;317(1):12-7 [2884564.001]
  • [Cites] J Neurosurg. 1990 Nov;73(5):674-83 [2213157.001]
  • [Cites] J Endocrinol Invest. 1999 Jan;22(1):64-5 [10090139.001]
  • [Cites] Acta Endocrinol (Copenh). 1991 Apr;124(4):487-91 [2031445.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1580-4 [7878022.001]
  • [Cites] Endocr Rev. 1996 Dec;17(6):610-38 [8969971.001]
  • [Cites] Eur J Nucl Med. 1997 Jul;24(7):728-31 [9211757.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Aug;81(8):3084-90 [8768879.001]
  • [Cites] Eur J Endocrinol. 1994 Jul;131(1):109-12 [8038902.001]
  • [Cites] Endocr J. 1999 Feb;46(1):113-23 [10426575.001]
  • [Cites] Eur J Endocrinol. 2003 Apr;148(4):433-42 [12656664.001]
  • [Cites] J Clin Endocrinol Metab. 1989 Jan;68(1):208-14 [2491862.001]
  • [Cites] Horm Metab Res. 1992 Jan;24(1):34-8 [1612557.001]
  • [Cites] J Clin Endocrinol Metab. 1974 May;38(5):742-5 [4207367.001]
  • [Cites] Metabolism. 1992 Sep;41(9 Suppl 2):62-5 [1518435.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jun;86(6):2849-53 [11397898.001]
  • [Cites] Pituitary. 2002;5(2):83-8 [12675505.001]
  • [Cites] J Neurosurg. 1993 Oct;79(4):521-7 [8410220.001]
  • (PMID = 15711028.001).
  • [ISSN] 1355-008X
  • [Journal-full-title] Endocrine
  • [ISO-abbreviation] Endocrine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Delayed-Action Preparations; 9002-71-5 / Thyrotropin; Q51BO43MG4 / Thyroxine; RWM8CCW8GP / Octreotide
  •  go-up   go-down


12. Beck-Peccoz P, Persani L: Medical management of thyrotropin-secreting pituitary adenomas. Pituitary; 2002;5(2):83-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medical management of thyrotropin-secreting pituitary adenomas.
  • Thyrotropin-secreting pituitary tumors (TSH-omas) are a rare cause of hyperthyroidism and account for less than 1% of all pituitary adenomas.
  • It is however noteworthy that the number of reported cases tripled in the last years as a consequence of the routine use of ultrasensitive immunometric assays for measuring TSH levels.
  • Contrary to previous RIAs, ultrasensitive TSH assays allow a clear distinction between patients with suppressed and those with non-suppressed circulating TSH concentrations, i.e. between patients with primary hyperthyroidism (Graves' disease or toxic nodular goiter) and those with central hyperthyroidism (TSH-oma or pituitary resistance to thyroid hormone action).
  • Failure to recognize the presence of a TSH-oma may result in dramatic consequences, such as improper thyroid ablation that may cause the pituitary tumor volume to further expand.
  • The medical treatment of TSH-omas mainly rests on the administration of somatostatin analogs, such as octreotide and lanreotide.
  • In fact, administration of dopamine agonists failed to persistently block TSH secretion in almost all patients and caused tumor shrinkage only in those with combined hypersecretion of TSH and PRL.
  • On the contrary, somatostatin analogs were effective in reducing TSH and alpha-subunit secretion in more than 90% of cases with consequent normalization of FT4 and FT3 levels and restoration of the euthyroid state in the majority of them.
  • Whether somatostatin analog treatment may be an alternative to surgery and/or irradiation in patients with TSH-oma remains to be established.
  • Nonetheless, the long-acting somatostatin preparations represent a useful tool for long-term treatment of such a rare pituitary tumors.
  • [MeSH-major] Adenoma / drug therapy. Adenoma / secretion. Pituitary Neoplasms / drug therapy. Pituitary Neoplasms / secretion. Thyrotropin / secretion

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 1986 Apr;62(4):704-11 [2419356.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Mar;74(3):690-4 [1740506.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Apr;86(4):1600-4 [11297590.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Apr;85(4):1487-91 [10770186.001]
  • [Cites] N Engl J Med. 1970 Nov 12;283(20):1077-80 [5470849.001]
  • [Cites] Ann Intern Med. 1993 Aug 1;119(3):236-40 [8323093.001]
  • [Cites] Clin Endocrinol (Oxf). 1994 Mar;40(3):421-8 [8187308.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Aug;75(2):540-6 [1353505.001]
  • [Cites] Ann Endocrinol (Paris). 1989;50(3):227-31 [2817765.001]
  • [Cites] N Engl J Med. 1987 Jul 2;317(1):12-7 [2884564.001]
  • [Cites] Trends Endocrinol Metab. 1992 Mar;3(2):41-5 [18407076.001]
  • [Cites] Clin Endocrinol (Oxf). 1991 Dec;35(6):455-66 [1837503.001]
  • [Cites] Eur J Endocrinol. 1994 Oct;131(4):355-8 [7921223.001]
  • [Cites] Clin Endocrinol (Oxf). 1994 Jan;40(1):137-43 [8306473.001]
  • [Cites] Clin Endocrinol (Oxf). 1997 Aug;47(2):207-14 [9302396.001]
  • [Cites] No To Shinkei. 1999 Oct;51(10):895-9 [10553592.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):476-86 [10022404.001]
  • [Cites] Thyroid. 1996 Aug;6(4):337-43 [8875757.001]
  • [Cites] J Clin Endocrinol Metab. 1991 Feb;72(2):415-21 [1704010.001]
  • [Cites] Thyroid. 1998 Feb;8(2):181-3 [9510128.001]
  • [Cites] Endocr Rev. 1996 Dec;17(6):610-38 [8969971.001]
  • [Cites] J Endocrinol Invest. 1985 Jun;8(3):193-8 [2863299.001]
  • [Cites] Pathol Res Pract. 1988 Sep;183(5):596-600 [3237550.001]
  • [Cites] J Clin Endocrinol Metab. 1990 Jul;71(1):19-25 [2370293.001]
  • [Cites] Am J Med. 1960 Mar;28:497-500 [14406535.001]
  • [Cites] Eur J Nucl Med. 1997 Jul;24(7):728-31 [9211757.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Mar;81(3):1164-8 [8772594.001]
  • [Cites] Horm Metab Res. 1979 Jul;11(7):452-3 [113330.001]
  • [Cites] Endocr Rev. 1993 Jun;14(3):348-99 [8319599.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Aug;81(8):3084-90 [8768879.001]
  • [Cites] Ann Intern Med. 1990 Jun 15;112(12 ):925-31 [2187392.001]
  • [Cites] Science. 2000 Apr 7;288(5463):154-7 [10753124.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Sep;57(3):401-4 [12201834.001]
  • [Cites] Clin Endocrinol (Oxf). 1985 Jul;23(1):35-42 [2411452.001]
  • [Cites] Ann Intern Med. 1982 Mar;96(3):281-6 [7059088.001]
  • [Cites] Endocr Pathol. 1995 Summer;6(2):125-134 [12114648.001]
  • [Cites] Endocr J. 2000 Dec;47(6):731-8 [11228048.001]
  • [Cites] Ann Intern Med. 1989 Nov 15;111(10):827-35 [2479309.001]
  • [Cites] Eur J Endocrinol. 1994 Feb;130(2):113-20 [8130883.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jun;86(6):2849-53 [11397898.001]
  • [Cites] J Neuroendocrinol. 1989 Oct 1;1(5):321-6 [19210422.001]
  • [Cites] Horm Res. 1987;26(1-4):79-99 [3297965.001]
  • (PMID = 12675505.001).
  • [ISSN] 1386-341X
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 9002-71-5 / Thyrotropin
  • [Number-of-references] 46
  •  go-up   go-down


13. Shimon I, Nass D, Gross DJ: Pituitary macroadenoma secreting thyrotropin and growth hormone: remission of bihormonal hypersecretion in response to lanreotide therapy. Pituitary; 2001 Sep;4(4):265-9
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pituitary macroadenoma secreting thyrotropin and growth hormone: remission of bihormonal hypersecretion in response to lanreotide therapy.
  • We report a case of mixed TSH- and GH-secreting pituitary adenoma in a 60-year-old female patient.
  • Blood hormone levels determinations revealed elevated thyroid hormones, TSH, and IGF-1 with a relatively low GH.
  • She underwent two pituitary surgical procedures followed by radiotherapy, but despite treatment was still hormonally active.
  • Pathological examination of the resected tumor immunostained positively for both TSH and GH.
  • The patient was subsequently treated with injections of lanreotide, a depot long-acting somatostatin analog, resulting in suppression of blood TSH, thyroid hormones, alpha-subunits, GH and IGF-1.
  • [MeSH-major] Adenoma / drug therapy. Adenoma / secretion. Antineoplastic Agents / therapeutic use. Human Growth Hormone / secretion. Peptides, Cyclic / therapeutic use. Pituitary Neoplasms / drug therapy. Pituitary Neoplasms / secretion. Somatostatin / analogs & derivatives. Somatostatin / therapeutic use. Thyrotropin / secretion

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 1986 Apr;62(4):704-11 [2419356.001]
  • [Cites] N Engl J Med. 1997 Feb 27;336(9):633-40 [9032050.001]
  • [Cites] Endocr J. 1999 Feb;46(1):159-65 [10426581.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Apr;85(4):1487-91 [10770186.001]
  • [Cites] Ann Intern Med. 1993 Aug 1;119(3):236-40 [8323093.001]
  • [Cites] Clin Endocrinol (Oxf). 1994 Mar;40(3):421-8 [8187308.001]
  • [Cites] Am J Pathol. 1989 Mar;134(3):605-13 [2466405.001]
  • [Cites] Eur J Endocrinol. 1999 Jun;140(6):528-37 [10366409.001]
  • [Cites] N Engl J Med. 1987 Jul 2;317(1):12-7 [2884564.001]
  • [Cites] Acta Med Okayama. 1991 Apr;45(2):107-15 [1867112.001]
  • [Cites] Endocr Rev. 1988 Nov;9(4):417-36 [2905987.001]
  • [Cites] Endocr Rev. 1996 Dec;17(6):610-38 [8969971.001]
  • [Cites] Endocr J. 1998 Apr;45(2):211-9 [9700474.001]
  • [Cites] Pituitary. 1999 May;1(3-4):243-50 [11081204.001]
  • [Cites] Semin Diagn Pathol. 1986 Feb;3(1):69-82 [3039632.001]
  • [Cites] Pituitary. 2000 May;2(4):289-94 [11081151.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Nov;85(11):4099-103 [11095439.001]
  • [Cites] Acta Endocrinol (Copenh). 1993 Dec;129(6):516-8 [8109184.001]
  • [Cites] Pituitary. 2000 Dec;3(4):231-8 [11788011.001]
  • [Cites] J Clin Invest. 1997 Feb 15;99(4):789-98 [9045884.001]
  • (PMID = 12501978.001).
  • [ISSN] 1386-341X
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Peptides, Cyclic; 0G3DE8943Y / lanreotide; 12629-01-5 / Human Growth Hormone; 51110-01-1 / Somatostatin; 9002-71-5 / Thyrotropin
  •  go-up   go-down


14. Blackhurst G, Strachan MW, Collie D, Gregor A, Statham PF, Seckl JE: The treatment of a thyrotropin-secreting pituitary macroadenoma with octreotide in twin pregnancy. Clin Endocrinol (Oxf); 2002 Sep;57(3):401-4
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The treatment of a thyrotropin-secreting pituitary macroadenoma with octreotide in twin pregnancy.
  • TSH-secreting pituitary tumours are rare but difficult to treat due to a combination of refractory hyperthyroidism and low surgical cure rates.
  • We describe the case of a 21-year-old woman who, despite twin pregnancy, became euthyroid and had dramatic tumour shrinkage on octreotide treatment.
  • To our knowledge, this is the first description of the use of octreotide for a TSH-secreting pituitary adenoma throughout pregnancy.
  • [MeSH-major] Adenoma / drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Octreotide / therapeutic use. Pituitary Neoplasms / drug therapy. Pregnancy Complications, Neoplastic / drug therapy. Thyrotropin / secretion

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12201834.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 9002-71-5 / Thyrotropin; RWM8CCW8GP / Octreotide
  •  go-up   go-down


15. Colao A, Filippella M, Di Somma C, Manzi S, Rota F, Pivonello R, Gaccione M, De Rosa M, Lombardi G: Somatostatin analogs in treatment of non-growth hormone-secreting pituitary adenomas. Endocrine; 2003 Apr;20(3):279-83
Hazardous Substances Data Bank. MENOTROPINS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatostatin analogs in treatment of non-growth hormone-secreting pituitary adenomas.
  • Besides well-known effects in GH-secreting adenomas, somatostatin analogs such as octreotide and lanreotide have been used in TSH-secreting adenomas and in the so-called clinically nonfunctioning adenomas.
  • The rationale for their use is based on the evidence that both these tumor types express large amounts of somatostatin receptor subtypes 2 and 5, which are preferentially bound by octreotide and lanreotide.
  • However, whether in TSH-secreting adenomas the results are excellent in the nonfunctioning type, the results are controversial.
  • [MeSH-major] Adenoma / drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Pituitary Neoplasms / drug therapy. Somatostatin / analogs & derivatives. Somatostatin / therapeutic use

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Drugs. 1997 Apr;53(4):681-99 [9098666.001]
  • [Cites] J Clin Invest. 1997 Nov 1;100(9):2386-92 [9410919.001]
  • [Cites] Eur J Nucl Med. 1994 Jul;21(7):647-50 [7957351.001]
  • [Cites] J Clin Endocrinol Metab. 1991 Oct;73(4):850-6 [1653785.001]
  • [Cites] Science. 1978 Oct 27;202(4366):390-402 [212832.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Nov;79(5):1416-23 [7962337.001]
  • [Cites] Eur J Endocrinol. 1995 May;132(5):559-64 [7749496.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Jan;83(1):248-52 [9435450.001]
  • [Cites] J Endocrinol Invest. 1998 May;21(5):284-90 [9648049.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Apr;85(4):1487-91 [10770186.001]
  • [Cites] N Engl J Med. 1996 Jan 25;334(4):246-54 [8532003.001]
  • [Cites] J Neurosurg. 1986 May;64(5):713-9 [3701419.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Sep;84(9):3268-76 [10487698.001]
  • [Cites] Ann Intern Med. 1993 Aug 1;119(3):236-40 [8323093.001]
  • [Cites] Q J Med. 1989 Feb;70(262):145-60 [2594955.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jun;86(6):2779-86 [11397887.001]
  • [Cites] Clin Endocrinol (Oxf). 1994 Mar;40(3):421-8 [8187308.001]
  • [Cites] Endocrinology. 2002 Oct;143(10):4123-30 [12239124.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Aug;75(2):540-6 [1353505.001]
  • [Cites] N Engl J Med. 1987 Jul 2;317(1):12-7 [2884564.001]
  • [Cites] J Endocrinol Invest. 1999 Mar;22(3):176-83 [10219884.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Nov;84(11):3859-66 [10566620.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Jul;79(1):145-51 [8027218.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):476-86 [10022404.001]
  • [Cites] Endocr Rev. 1996 Dec;17(6):610-38 [8969971.001]
  • [Cites] Endocr Rev. 1991 Nov;12(4):450-82 [1684746.001]
  • [Cites] Clin Endocrinol (Oxf). 1999 Sep;51(3):281-4 [10469006.001]
  • [Cites] Clin Endocrinol (Oxf). 2001 Jan;54(1):23-30 [11167922.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Aug;79(2):461-5 [8045964.001]
  • [Cites] Eur J Nucl Med. 1997 Jul;24(7):728-31 [9211757.001]
  • [Cites] Clin Endocrinol (Oxf). 2000 Apr;52(4):437-45 [10762286.001]
  • [Cites] Neurosurgery. 1997 Oct;41(4):786-95; discussion 796-7 [9316039.001]
  • [Cites] Q J Med. 1989 May;71(265):417-27 [2602541.001]
  • [Cites] Intern Med. 1998 Dec;37(12):1027-30 [9932634.001]
  • [Cites] Science. 2000 Apr 7;288(5463):154-7 [10753124.001]
  • [Cites] Ann Endocrinol (Paris). 2002 Apr;63(2 Pt 3):2S5-12 [12037501.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Sep;83(9):3034-40 [9745397.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Nov;75(5):1310-7 [1430093.001]
  • [Cites] Acta Endocrinol (Copenh). 1991 Dec;125(6):637-42 [1789059.001]
  • [Cites] J Clin Endocrinol Metab. 1993 May;76(5):1089-94 [8496297.001]
  • [Cites] Pituitary. 1999;1(2):115-20 [11081189.001]
  • [Cites] Eur J Endocrinol. 1999 Oct;141(4):396-408 [10526255.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jun;86(6):2849-53 [11397898.001]
  • [Cites] J Endocrinol. 1981 Jul;90(1):3p-10p [6114978.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Jun;81(6):2089-97 [8964833.001]
  • [Cites] Eur J Endocrinol. 2000 Oct;143 Suppl 1:S43-51 [11068939.001]
  • (PMID = 12721508.001).
  • [ISSN] 1355-008X
  • [Journal-full-title] Endocrine
  • [ISO-abbreviation] Endocrine
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 51110-01-1 / Somatostatin; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone; 9002-71-5 / Thyrotropin; 9002-72-6 / Growth Hormone
  • [Number-of-references] 48
  •  go-up   go-down


16. Caron P, Arlot S, Bauters C, Chanson P, Kuhn JM, Pugeat M, Marechaud R, Teutsch C, Vidal E, Sassano P: Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas. J Clin Endocrinol Metab; 2001 Jun;86(6):2849-53
Hazardous Substances Data Bank. LIOTHYRONINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas.
  • The presence of somatostatin receptors on TSH-secreting pituitary adenomas allows treatment of central hyperthyroidism with somatostatin analogs.
  • Six women and 5 men (mean +/- SEM age, 43 +/- 3 yr) presented TSH-secreting pituitary adenomas (micro, n = 2; macro, n = 9).
  • Seven patients had previously been treated with partial surgical removal (n = 6) and/or external radiation (n = 4) of their adenoma at least 1 yr before the study, whereas 4 patients had not been treated before somatostatin analog therapy.
  • TSH, free T(4), and free T(3) levels were in the normal range during treatment with sc injections (n = 9) or continuous infusion (n = 2) of octreotide (280 +/- 25 microg/day).
  • After 3 months of Octreotide-LAR treatment, TSH, free T(4)/T(3), and alpha-subunit levels decreased, and 10 patients were euthyroid with normal free T(4) levels.
  • There were no statistically significant differences in the TSH and free T(4) responses to sc octreotide or im Octreotide-LAR between previously untreated patients and patients who had undergone surgical resection and/or pituitary radiation before somatostatin analog treatment.
  • During Octreotide-LAR treatment, minor digestive problems or moderate discomfort at the injection site, lasting less than 48 h, were reported in 6 and 5 patients, respectively.
  • Gallbladder echographies did not reveal new gallstones during Octreotide-LAR treatment.
  • In conclusion, this study shows that monthly im Octreotide-LAR is as effective as daily sc octreotide in controlling hyperthyroidism in patients with TSH-secreting pituitary adenomas, in both previously untreated patients and patients treated with surgery and/or pituitary radiotherapy.
  • Therefore, Octreotide-LAR appears to be a useful therapeutic tool to facilitate medical treatment of TSH-secreting pituitary adenomas in patients who need long-term somatostatin analog therapy.
  • [MeSH-major] Adenoma / drug therapy. Adenoma / secretion. Antineoplastic Agents, Hormonal / therapeutic use. Octreotide / therapeutic use. Pituitary Neoplasms / drug therapy. Pituitary Neoplasms / secretion. Thyrotropin / secretion

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11397898.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Delayed-Action Preparations; 06LU7C9H1V / Triiodothyronine; 9002-71-5 / Thyrotropin; Q51BO43MG4 / Thyroxine; RWM8CCW8GP / Octreotide
  •  go-up   go-down


17. Dhillon KS, Cohan P, Kelly DF, Darwin CH, Iyer KV, Chopra IJ: Treatment of hyperthyroidism associated with thyrotropin-secreting pituitary adenomas with iopanoic acid. J Clin Endocrinol Metab; 2004 Feb;89(2):708-11
Hazardous Substances Data Bank. IOPANOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of hyperthyroidism associated with thyrotropin-secreting pituitary adenomas with iopanoic acid.
  • TSH-secreting tumors comprise less than 2% of all pituitary adenomas.
  • All patients present with hyperthyroidism with a detectable TSH level, and a majority have macroadenomas.
  • However, they have not been employed in the treatment of central hyperthyroidism.
  • In case 1, free T(3) index improved from a value of 634 to 175 (normal range 78-162) after 3 d of therapy with iopanoic acid.
  • In case 2, free T(3) by dialysis improved from 697 pg/dl (10.7 pmol/liter) to 195 pg/dl (3.0 pmol/liter) (normal range 210-440 pg/dl; 3.2-6.7 pmol/liter) after 7 d of therapy with iopanoic acid.
  • [MeSH-major] Adenoma / secretion. Adenoma / surgery. Hyperthyroidism / drug therapy. Iopanoic Acid / therapeutic use. Pituitary Neoplasms / secretion. Pituitary Neoplasms / surgery. Thyrotropin / secretion

  • MedlinePlus Health Information. consumer health - Hyperthyroidism.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14764785.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9002-71-5 / Thyrotropin; FE9794P71J / Iopanoic Acid
  •  go-up   go-down


18. Gourgiotis L, Skarulis MC, Brucker-Davis F, Oldfield EH, Sarlis NJ: Effectiveness of long-acting octreotide in suppressing hormonogenesis and tumor growth in thyrotropin-secreting pituitary adenomas: report of two cases. Pituitary; 2001 Aug;4(3):135-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effectiveness of long-acting octreotide in suppressing hormonogenesis and tumor growth in thyrotropin-secreting pituitary adenomas: report of two cases.
  • BACKGROUND: The subcutaneous (s.c.) administration of somatostatin analogs, such as octreotide acetate (SMS) and lanreotide, in patients with thyrotropin (TSH)-secreting pituitary adenomas (TSPA's)--thyrotropinomas with residual tumor after initial surgical therapy is effective in controlling hyperthyroidism, as well as curtailing tumor growth in the majority of patients.
  • MATERIALS AND METHODS: We present two cases of TSPA's with residual tumor following transsphenoidal adenomectomy.
  • The presence and extent of tumoral TSH hypersecretion was assessed by standard biochemical and dynamic endocrine testing, while tumor size was evaluated by conventional radiographic techniques.
  • RESULTS: In both patients, TSH secretion was effectively suppressed by SMS-LAR.
  • [MeSH-major] Adenoma / drug therapy. Hormones / therapeutic use. Octreotide / therapeutic use. Pituitary Neoplasms / drug therapy. Thyrotropin / secretion
  • [MeSH-minor] Aged. Female. Humans. Middle Aged. Radionuclide Imaging. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hormones.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Drugs. 1997 Apr;53(4):681-99 [9098666.001]
  • [Cites] J Clin Invest. 1997 Nov 1;100(9):2386-92 [9410919.001]
  • [Cites] Ital J Gastroenterol Hepatol. 1999 Oct;31 Suppl 2:S216-8 [10604134.001]
  • [Cites] J Endocrinol Invest. 1998 Sep;21(8):512-9 [9801992.001]
  • [Cites] Endocrinology. 1983 Jun;112(6):1937-42 [6133740.001]
  • [Cites] Clin Endocrinol (Oxf). 2000 Nov;53(5):577-86 [11106918.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jan;82(1):23-8 [8989226.001]
  • [Cites] Clin Endocrinol (Oxf). 1999 Feb;50(2):245-51 [10396369.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Apr;85(4):1487-91 [10770186.001]
  • [Cites] J Endocrinol Invest. 1998 Dec;21(11):775-8 [9972679.001]
  • [Cites] Metabolism. 1996 Aug;45(8 Suppl 1):75-9 [8769389.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jun;86(6):2779-86 [11397887.001]
  • [Cites] Clin Endocrinol (Oxf). 1994 Mar;40(3):421-8 [8187308.001]
  • [Cites] Endocrinol Metab Clin North Am. 1992 Sep;21(3):737-52 [1355729.001]
  • [Cites] N Engl J Med. 1987 Jul 2;317(1):12-7 [2884564.001]
  • [Cites] Cancer. 1997 Feb 15;79(4):804-12 [9024719.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Feb;76(2):529-33 [8432799.001]
  • [Cites] J Neurosurg. 1990 Nov;73(5):674-83 [2213157.001]
  • [Cites] Endocrinol Metab Clin North Am. 1998 Mar;27(1):187-203 [9534036.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):476-86 [10022404.001]
  • [Cites] Horm Res. 2000;53 Suppl 3:76-87 [10971110.001]
  • [Cites] Thyroid. 2000 Nov;10 (11):1001-7 [11128714.001]
  • [Cites] Clin Endocrinol (Oxf). 1997 Nov;47(5):589-98 [9425399.001]
  • [Cites] Clin Endocrinol (Oxf). 2001 Jan;54(1):23-30 [11167922.001]
  • [Cites] Eur J Nucl Med. 1997 Jul;24(7):728-31 [9211757.001]
  • [Cites] Mayo Clin Proc. 1997 Oct;72(10):893-900 [9379690.001]
  • [Cites] Mol Endocrinol. 2001 Sep;15(9):1529-38 [11518802.001]
  • [Cites] Ann Intern Med. 1989 Jan 1;110(1):35-50 [2535688.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Nov;75(5):1318-25 [1358910.001]
  • [Cites] Neurosurgery. 1997 Oct;41(4):786-95; discussion 796-7 [9316039.001]
  • [Cites] Endocr J. 1999 Feb;46(1):113-23 [10426575.001]
  • [Cites] Pituitary. 1998 Apr;1(1):69-81 [11081185.001]
  • [Cites] Clin Endocrinol (Oxf). 1999 Sep;51(3):275-80 [10469005.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Sep;83(9):3034-40 [9745397.001]
  • [Cites] J Clin Endocrinol Metab. 1989 Jan;68(1):208-14 [2491862.001]
  • [Cites] Ann Intern Med. 1989 Nov 15;111(10):827-35 [2479309.001]
  • [Cites] Presse Med. 2000 Nov 4;29(33):1818-9 [11109436.001]
  • [Cites] Eur J Endocrinol. 1999 Oct;141(4):396-408 [10526255.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jun;86(6):2849-53 [11397898.001]
  • [Cites] Pituitary. 2000 Oct;3(2):61-5 [11141697.001]
  • [Cites] J Clin Invest. 1997 Feb 15;99(4):789-98 [9045884.001]
  • [Cites] Metabolism. 1996 Aug;45(8 Suppl 1):67-71 [8769387.001]
  • [Cites] Neuroendocrinology. 1989 Mar;49(3):267-74 [2716953.001]
  • (PMID = 12138986.001).
  • [ISSN] 1386-341X
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hormones; 9002-71-5 / Thyrotropin; RWM8CCW8GP / Octreotide
  •  go-up   go-down


19. Kuhn JM, Arlot S, Lefebvre H, Caron P, Cortet-Rudelli C, Archambaud F, Chanson P, Tabarin A, Goth MI, Blumberg J, Catus F, Ispas S, Beck-Peccoz P: Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide. J Clin Endocrinol Metab; 2000 Apr;85(4):1487-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide.
  • Somatostatin analogs have been shown to be effective for the treatment of TSH-secreting pituitary adenomas.
  • Eighteen patients with hyperthyroidism related to a TSH-secreting pituitary adenoma, evidenced by pituitary magnetic resonance imaging, were studied.
  • Clinical and biological evaluations (plasma TSH, free alpha-subunit, fT4, fT3, and lanreotide levels) were performed before and in months 1, 3, and 6 of treatment.
  • During therapy, the plasma TSH level decreased from 2.72 +/- 0.32 to 1.89 +/-0.27 mU/L (P < 0.01), with parallel significant changes in free alpha-subunit.
  • No statistically significant change in mean adenoma size was observed after 6 months of treatment.
  • Side-effects, including pain at the injection point, abdominal cramps, and diarrhea, were mild and transient and did not lead to interruption of the treatment.
  • SR-L appears to be able to suppress clinical signs of hyperthyroidism in our series of patients with TSH-secreting pituitary adenomas.
  • The analog also reduces plasma TSH and thyroid hormone levels, which were normalized in 13 of 16 cases.
  • The effect was maintained throughout the treatment using 2 or 3 SR-L injections monthly without any problem of tolerance.
  • We conclude that SR-L is a safe and effective treatment of thyrotropinomas and avoids the drawbacks of the modes of administration of other somatostatin analogs, given three times daily.
  • [MeSH-major] Adenoma / drug therapy. Antineoplastic Agents / therapeutic use. Peptides, Cyclic / therapeutic use. Pituitary Neoplasms / drug therapy. Somatostatin / analogs & derivatives. Thyrotropin / secretion

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • Hazardous Substances Data Bank. LIOTHYRONINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10770186.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Peptides, Cyclic; 06LU7C9H1V / Triiodothyronine; 118992-92-0 / lanreotide; 51110-01-1 / Somatostatin; 9002-71-5 / Thyrotropin; Q51BO43MG4 / Thyroxine
  •  go-up   go-down


20. Baba T, Endo T, Kitajima Y, Kamiya H, Moriwaka O, Saito T: Spontaneous ovarian hyperstimulation syndrome and pituitary adenoma: incidental pregnancy triggers a catastrophic event. Fertil Steril; 2009 Jul;92(1):390.e1-3
Hazardous Substances Data Bank. MENOTROPINS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous ovarian hyperstimulation syndrome and pituitary adenoma: incidental pregnancy triggers a catastrophic event.
  • OBJECTIVE: To report a rare case of spontaneous ovarian hyperstimulation syndrome (OHSS) associated with spontaneous pregnancy and a FSH-secreting pituitary adenoma.
  • In addition, her TSH level was normal, and hCG was appropriate for the date of pregnancy.
  • Subsequently, the patient developed massive thrombophlebitis in her right internal jugular and subclavian veins.
  • No mutations of the FSH receptor, LH receptor, or aromatase genes were detected, but magnetic resonance imaging (MRI) of the head revealed a pituitary adenoma.
  • CONCLUSION(S): A gonadotropin-secreting adenoma caused ovarian hyperstimulation (ovarian enlargement and hyperestrogenemia).
  • [MeSH-major] Adenoma / complications. Ovarian Hyperstimulation Syndrome / complications. Pituitary Neoplasms / complications. Pregnancy Complications / etiology
  • [MeSH-minor] Adult. Anticoagulants / therapeutic use. Dilatation and Curettage. Estrogens / blood. Female. Follicle Stimulating Hormone / secretion. Humans. Paracentesis. Pregnancy. Thrombosis / complications. Thrombosis / drug therapy. Ultrasonography, Prenatal / adverse effects


21. Marek J: [Pituitary adenomas--where is the treatment heading at the beginning of the 21st century?]. Vnitr Lek; 2010 Jul;56(7):690-4
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pituitary adenomas--where is the treatment heading at the beginning of the 21st century?].
  • To treat pituitary adenomas, three modes of treatment are usually combined: neurosurgery, radiation and pharmacological.
  • Prolactinomas are an exception with predominantly pharmacological management.
  • Patients with acromegaly are usually diagnosed late and thus many neurosurgeries fail to completely remove the adenoma.
  • Any residual tumour tissue is usually irradiated with the Leksell Gamma Knife, and dopamine agonists, somatostatine analogues or growth hormone receptor antagonists are used to normalize the hormonal hypersecretion until the complete effect of the radiation.
  • The same surgical and Gamma Knife procedures are used in patients with the Cushing's disease and TSH-secreting adenomas.
  • Ketoconazole, metyrapone and cabergoline are used until the radiation effect in the Cushing's disease is complete, similarly, somatostatine analogues are used in TSH-secreting adenomas.
  • Nonfunctional adenomas are less responsive to pharmacological treatment.
  • [MeSH-major] Adenoma / therapy. Pituitary Neoplasms / therapy
  • [MeSH-minor] Acromegaly / etiology. Humans. Pituitary ACTH Hypersecretion / etiology. Prolactinoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20842914.001).
  • [ISSN] 0042-773X
  • [Journal-full-title] Vnitr̆ní lékar̆ství
  • [ISO-abbreviation] Vnitr Lek
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Czech Republic
  •  go-up   go-down


22. Orrego JJ, Barkan AL: Pituitary disorders. Drug treatment options. Drugs; 2000 Jan;59(1):93-106
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pituitary disorders. Drug treatment options.
  • Pituitary tumours can cause symptoms of mass effect and hormonal hypersecretion that can be reversed with surgical resection or debulking of the adenoma, radiotherapy, or medical treatment.
  • Transsphenoidal adenomectomy is the treatment of choice for acromegaly, Cushing's disease, gonadotropin-secreting tumours; and thyrotropin (TSH)-secreting adenomas.
  • Pituitary irradiation and medical therapy are secondary options.
  • Conversely, medical treatment is the primary choice for prolactinomas.
  • Dopamine agonists are very effective in the treatment of prolactin (PRL)-secreting tumours, with rates of control as high as 80 to 90% for microprolactinomas (< 10 mm) and 60 to 75% for macroprolactinomas (> or = 10 mm).
  • Somatostatin analogues have also shown efficacy in patients with acromegaly who have not responded to surgery or in patients with TSH-secreting adenomas who have not improved with surgery and radiotherapy.
  • Although the classic sequence of loss of pituitary secretion is growth hormone (GH), gonadotropins, TSH, and corticotropin (ACTH), the order to begin the replacement therapy of the deficient hormone(s) is cortisol, thyroxine, androgens/estrogens and, if necessary, GH.
  • In general, the hormone replacement therapy is lifelong.
  • [MeSH-major] Adenoma / drug therapy. Hypopituitarism / drug therapy. Pituitary Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 1997 Nov 1;100(9):2386-92 [9410919.001]
  • [Cites] Lancet. 1998 Jul 11;352(9122):127-34 [9672293.001]
  • [Cites] N Engl J Med. 1997 Jan 16;336(3):172-7 [8988897.001]
  • [Cites] J Clin Invest. 1993 Aug;92(2):695-701 [8349808.001]
  • [Cites] N Engl J Med. 1997 Oct 30;337(18):1285-92 [9345079.001]
  • [Cites] N Engl J Med. 1996 Mar 14;334(11):707-14 [8594431.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Mar;82(3):876-83 [9062500.001]
  • [Cites] N Engl J Med. 1994 Jul 21;331(3):174-80 [8008032.001]
  • [Cites] N Engl J Med. 1983 Sep 22;309(12 ):704-9 [6888442.001]
  • [Cites] J Androl. 1994 May-Jun;15(3):212-5 [7928661.001]
  • [Cites] Clin Endocrinol (Oxf). 1996 Aug;45(2):171-8 [8881449.001]
  • [Cites] J Clin Endocrinol Metab. 1990 May;70(5):1426-30 [2159485.001]
  • [Cites] Eur J Endocrinol. 1995 May;132(5):559-64 [7749496.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Aug;83(8):2646-52 [9709926.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Feb;82(2):634-7 [9024267.001]
  • [Cites] J Clin Endocrinol Metab. 1989 May;68(5):917-24 [2565913.001]
  • [Cites] Eur J Endocrinol. 1996 Nov;135(5):559-67 [8980158.001]
  • [Cites] Clin Obstet Gynecol. 1996 Jun;39(2):506-10 [8734015.001]
  • [Cites] J Clin Endocrinol Metab. 1988 Jul;67(1):180-5 [2967850.001]
  • [Cites] Ann Intern Med. 1993 Aug 1;119(3):236-40 [8323093.001]
  • [Cites] N Engl J Med. 1994 Oct 6;331(14):904-9 [7915824.001]
  • [Cites] Clin Endocrinol (Oxf). 1994 Mar;40(3):421-8 [8187308.001]
  • [Cites] Endocrinol Jpn. 1992 Aug;39(4):385-95 [1332855.001]
  • [Cites] Lancet. 1976 Aug 21;2(7982):426 [73893.001]
  • [Cites] J Endocrinol Invest. 1990 Dec;13(11):923-9 [2090672.001]
  • [Cites] J Clin Endocrinol Metab. 1990 Jul;71(1):216-22 [2115044.001]
  • [Cites] J Biol Chem. 1994 Jun 3;269(22):15892-7 [8195244.001]
  • [Cites] J Clin Endocrinol Metab. 1988 Jun;66(6):1144-51 [3372679.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Feb;82(2):518-23 [9024247.001]
  • [Cites] Drugs. 1998 Jul;56(1):49-57 [9664198.001]
  • [Cites] J Clin Endocrinol Metab. 1981 Oct;53(4):737-43 [7287863.001]
  • [Cites] N Engl J Med. 1987 Jul 2;317(1):12-7 [2884564.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Feb;82(2):514-7 [9024246.001]
  • [Cites] Clin Endocrinol (Oxf). 1990 Aug;33(2):161-9 [2225475.001]
  • [Cites] Acta Endocrinol (Copenh). 1988 Nov;119(3):435-42 [2847474.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Oct;82(10):3187-91 [9329336.001]
  • [Cites] Horm Res. 1996;46(4-5):155-9 [8950613.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):382-95 [9467546.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jan;82(1):18-22 [8989225.001]
  • [Cites] N Engl J Med. 1985 Sep 12;313(11):656-9 [4022058.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):476-86 [10022404.001]
  • [Cites] Lancet. 1997 Feb 8;349(9049):413-7 [9033482.001]
  • [Cites] Endocr Rev. 1996 Dec;17(6):610-38 [8969971.001]
  • [Cites] J Clin Pharmacol. 1976 Nov-Dec;16(11-12):645-51 [993360.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Jan;74(1):75-83 [1727832.001]
  • [Cites] Endocrinol Metab Clin North Am. 1999 Mar;28(1):143-69, vii [10207689.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Aug;79(2):461-5 [8045964.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Nov;80(11):3267-72 [7593436.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):374-8 [9467544.001]
  • [Cites] J Endocrinol Invest. 1994 Feb;17(2):135-9 [8006335.001]
  • [Cites] Ann Intern Med. 1998 Sep 15;129(6):472-83 [9735086.001]
  • [Cites] Hum Reprod Update. 1995 Mar;1(2):188-99 [15726772.001]
  • [Cites] Obstet Gynecol. 1989 Mar;73(3 Pt 2):517-20 [2915884.001]
  • [Cites] Ann Med. 1998 Apr;30(2):159-68 [9667794.001]
  • [Cites] Lancet. 1997 Jul 26;350(9073):275-9 [9242812.001]
  • [Cites] Neurosurgery. 1997 Oct;41(4):786-95; discussion 796-7 [9316039.001]
  • [Cites] Endocr Rev. 1993 Aug;14 (4):443-58 [7693447.001]
  • [Cites] N Engl J Med. 1995 Mar 23;332(12):791-803 [7862184.001]
  • [Cites] J Clin Endocrinol Metab. 1985 Sep;61(3):580-4 [2410444.001]
  • [Cites] Ann Intern Med. 1992 Nov 1;117(9):711-8 [1416572.001]
  • [Cites] Ann Intern Med. 1990 May 1;112(9):668-73 [1970714.001]
  • [Cites] Endocrinol Metab Clin North Am. 1994 Dec;23(4):749-72 [7705318.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):440-8 [10022398.001]
  • [Cites] N Engl J Med. 1994 Jun 9;330(23):1651-62 [8043090.001]
  • [Cites] Drugs. 1996 Jun;51(6):954-65 [8736617.001]
  • [Cites] Clin Endocrinol (Oxf). 1997 Mar;46(3):255-61 [9156031.001]
  • [Cites] Clin Endocrinol (Oxf). 1997 Mar;46(3):263-8 [9156032.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Nov;75(5):1204-10 [1430080.001]
  • [Cites] N Engl J Med. 1996 Oct 17;335(16):1206-12 [8815944.001]
  • [Cites] Fertil Steril. 1993 Mar;59(3):671-3 [8458475.001]
  • [Cites] J Clin Endocrinol Metab. 1985 Apr;60(4):698-705 [3882737.001]
  • [Cites] Endocrinol Metab Clin North Am. 1992 Sep;21(3):713-35 [1355728.001]
  • [Cites] J Clin Endocrinol Metab. 1984 Dec;59(6):1220-3 [6436289.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):379-81 [9467545.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jan;82(1):3-8 [8989221.001]
  • [Cites] J Clin Endocrinol Metab. 1989 Sep;69(3):500-9 [2760167.001]
  • [Cites] Clin Endocrinol (Oxf). 1998 Mar;48(3):311-6 [9578821.001]
  • [Cites] Clin Endocrinol (Oxf). 1991 Aug;35(2):169-78 [1657460.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Dec;80(12):3567-75 [8530600.001]
  • [Cites] Horm Res. 1997;48 Suppl 5:21-30 [9434041.001]
  • [Cites] N Engl J Med. 1979 Mar 1;300(9):459-64 [215912.001]
  • [Cites] Drugs. 1998 Feb;55(2):253-8; discussion 259 [9506244.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Apr;82(4):996-1000 [9100563.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Sep;80(9):2768-75 [7673422.001]
  • [Cites] Ann Surg. 1994 Apr;219(4):416-25 [8161268.001]
  • [Cites] J Clin Endocrinol Metab. 1993 May;76(5):1363-8 [8496331.001]
  • [Cites] Arch Intern Med. 1991 Aug;151(8):1573-8 [1872661.001]
  • (PMID = 10718101.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Gonadotropins, Pituitary; 12629-01-5 / Human Growth Hormone; 9002-60-2 / Adrenocorticotropic Hormone; 9002-62-4 / Prolactin; 9002-71-5 / Thyrotropin
  • [Number-of-references] 88
  •  go-up   go-down


23. Colao A, Dorato M, Pulcrano M, Rossi FW, Auriemma RS, Lombardi G, Lastoria S: [Somatostatin analogs in the clinical management of pituitary neoplasms]. Minerva Endocrinol; 2001 Sep;26(3):181-91
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The medical approach to patients with secreting or clinically non-functioning pituitary adenoma as made considerable progress thanks to the use of new somatostatin analogs.
  • Good results were obtained using slow-release analog treatment also in TSH-secreting adenomas, whereas the therapeutic efficacy of these peptides in clinically non-functioning adenomas is still controversial.
  • Treatment with somatostatin analogs improves symptoms, normalises hormone secretion and in some cases may induce a reduction in the volume of pituitary adenomas.
  • Scintigraphy with octreotide may help to select patients who respond to this form of treatment.
  • [MeSH-major] Adenoma / drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Octreotide / analogs & derivatives. Octreotide / therapeutic use. Pentetic Acid / analogs & derivatives. Peptides, Cyclic / therapeutic use. Pituitary Neoplasms / drug therapy. Somatostatin / therapeutic use
  • [MeSH-minor] Acromegaly / drug therapy. Adolescent. Adrenal Gland Neoplasms / radionuclide imaging. Adult. Aged. Carcinoma / radionuclide imaging. Humans. Indium Radioisotopes / therapeutic use. Insulin-Like Growth Factor I / secretion. Kidney Neoplasms / radionuclide imaging. Melanoma / radionuclide imaging. Middle Aged. Pheochromocytoma / radionuclide imaging. Predictive Value of Tests. Prolactinoma / drug therapy. Radiopharmaceuticals / therapeutic use. Sensitivity and Specificity. Thymoma / radionuclide imaging. Thymus Neoplasms / radionuclide imaging. Thyroid Neoplasms / radionuclide imaging. Thyrotropin / secretion. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11753242.001).
  • [ISSN] 0391-1977
  • [Journal-full-title] Minerva endocrinologica
  • [ISO-abbreviation] Minerva Endocrinol.
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Indium Radioisotopes; 0 / Peptides, Cyclic; 0 / Radiopharmaceuticals; 118992-92-0 / lanreotide; 142694-57-3 / SDZ 215-811; 51110-01-1 / Somatostatin; 67763-96-6 / Insulin-Like Growth Factor I; 7A314HQM0I / Pentetic Acid; 9002-71-5 / Thyrotropin; RWM8CCW8GP / Octreotide
  • [Number-of-references] 95
  •  go-up   go-down


24. Taylor TJ, Donlon SS, Bale AE, Smallridge RC, Francis TB, Christensen RS, Burma KD: Treatment of a thyrotropinoma with octreotide-LAR in a patient with multiple endocrine neoplasia-1. Thyroid; 2000 Nov;10(11):1001-7
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of a thyrotropinoma with octreotide-LAR in a patient with multiple endocrine neoplasia-1.
  • OBJECTIVE: To note that a thyrotropin (TSH)-secreting macroadenoma may be part of the multiple endocrine neoplasia-1 (MEN-1) syndrome and to report the use of octreotide-LAR (OCT-LAR) to treat a TSH-secreting macroadenoma in a patient with MEN-1 with previous surgery for hyperparathyroidism and gastrinoma.
  • METHODS: We present a patient with a TSH-secreting pituitary macroadenoma and report the results of her endocrine, genetic, radiologic, and nuclear medicine testing and her response to treatment with octreotide (OCT), octreotide-LAR, and estrogen.
  • RESULTS: This patient's TSH-induced hyperthyroidism responded to octreotide for 5 months and octreotide-LAR for more than 11 months.
  • (1) The use of octreotide-LAR to treat both a TSH-secreting pituitary tumor and a gastrinoma over 12 months;.
  • [MeSH-major] Adenoma / drug therapy. Hormones / administration & dosage. Multiple Endocrine Neoplasia Type 1 / drug therapy. Octreotide / administration & dosage. Thyroid Neoplasms / drug therapy. Thyrotropin / secretion
  • [MeSH-minor] Estrogens / administration & dosage. Female. Humans. Hypercalcemia / etiology. Hyperthyroidism / drug therapy. Hyperthyroidism / etiology. Hyperthyroidism / radionuclide imaging. Middle Aged

  • Genetic Alliance. consumer health - Multiple Endocrine Neoplasia.
  • MedlinePlus Health Information. consumer health - Hormones.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11128714.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogens; 0 / Hormones; 9002-71-5 / Thyrotropin; RWM8CCW8GP / Octreotide
  •  go-up   go-down


25. Oliveira JH, Barbosa ER, Kasamatsu T, Abucham J: Evidence for thyroid hormone as a positive regulator of serum thyrotropin bioactivity. J Clin Endocrinol Metab; 2007 Aug;92(8):3108-13
Hazardous Substances Data Bank. RICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: The regulation of TSH bioactivity in humans is not completely understood.
  • OBJECTIVE: The aim of the study was to investigate the role of serum thyroid hormones in regulating the bioactivity of TSH.
  • DESIGN: We determined in vitro TSH bioactivity and glycosylation in nine patients (six females and three males, age 41.3 yr) with primary hypothyroidism before and after L-T(4) replacement, in 11 age- and sex-comparable controls (seven females and four males, age 37.6 yr), and in two thyroidectomized patients with TSH-secreting adenomas during and after L-T(4) withdrawal.
  • METHODS: In vitro TSH bioactivity was measured by a sensitive and specific bioassay based on cAMP generation by Chinese hamster ovary cells transfected with human TSH receptor.
  • TSH glycosylation was assessed by concanavalin A lectin and ricin column affinity chromatography.
  • RESULTS: In vitro TSH bioactivity in hypothyroid patients was low as compared with controls (0.48 +/- 0.1 vs. 1.1 +/- 0.2; P = 0.004) and increased during L-T(4) (0.48 +/- 0.1 vs. 0.8 +/- 0.1; P = 0.01).
  • A strong significant correlation (r = +0.80; P = 0.004, Spearman) was observed between the absolute increments of serum TSH bioactivity and T(3) during L-T(4) replacement.
  • The degree of sialylation was elevated in hypothyroid patients before treatment (47 +/- 2.4% vs. 29 +/- 4.3%; P = 0.002) and decreased significantly after L-T(4) (47 +/- 2.4% vs. 33 +/- 4.3%; P = 0.02).
  • The mannose content of serum TSH in hypothyroid patients was similar to controls and did not change during L-T(4).
  • In vitro TSH bioactivity also decreased in patients with TSH-secreting adenomas during L-T(4) withdrawal.
  • CONCLUSION: These data indicate that serum thyroid hormone level is a positive regulator of TSH bioactivity.
  • [MeSH-minor] Adenoma / metabolism. Adult. Animals. CHO Cells. Chromatography, Affinity. Concanavalin A / chemistry. Cricetinae. Cricetulus. Cyclic AMP / biosynthesis. Female. Glycosylation. Hormone Replacement Therapy. Humans. Hypothyroidism / blood. Hypothyroidism / drug therapy. Immunoassay. Male. Mannose / blood. Middle Aged. Neuraminidase / chemistry. Receptors, Thyrotropin / genetics. Receptors, Thyrotropin / metabolism. Ricin / chemistry. Thyroidectomy. Thyroxine / therapeutic use. Transfection

  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17504893.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Thyrotropin; 0 / Thyroid Hormones; 11028-71-0 / Concanavalin A; 9002-71-5 / Thyrotropin; 9009-86-3 / Ricin; E0399OZS9N / Cyclic AMP; EC 3.2.1.18 / Neuraminidase; PHA4727WTP / Mannose; Q51BO43MG4 / Thyroxine
  •  go-up   go-down


26. Mezosi E, Nemes O: [Treatment of pituitary adenomas]. Orv Hetil; 2009 Sep 27;150(39):1803-10
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of pituitary adenomas].
  • The first-line therapy of prolactinomas are the dopamine agonists, and the aims of the treatment are to normalize the prolactin level, restore fertility in child-bearing age, decrease tumor mass, save or improve the residual pituitary function and inhibit the relapse of the disease.
  • In case of tumors with good therapeutic response, medical therapy can be withdrawn after 3-5 years; hyperprolactinemia will not recur in 2/3 of these patients.
  • Neurosurgery is the primary therapy of GH-, ACTH-, TSH-producing and inactive adenomas.
  • Acromegalic patients with unresectable tumors have a great benefit from somatostatin analog treatment.
  • The growth hormone receptor antagonist pegvisomant is the newest modality for the treatment of acromegaly.
  • The medical therapy of Cushing's disease is still based on the inhibition of steroid production.
  • The rare TSH-producing tumor can respond to both dopamine agonist and somatostatin analog therapy.
  • The application of conventional radiotherapy has decreased; radiotherapy is mainly used in the treatment of invasive, incurable or malignant tumors.
  • Further studies are needed to elucidate the exact role of radiosurgery and fractionated stereotaxic irradiation in the treatment of pituitary tumors.
  • [MeSH-major] Adenoma / therapy. Pituitary Hormones / blood. Pituitary Neoplasms / therapy
  • [MeSH-minor] ACTH-Secreting Pituitary Adenoma / therapy. Acromegaly / drug therapy. Acromegaly / etiology. Adrenocorticotropic Hormone / blood. Aminoquinolines / therapeutic use. Bromocriptine / therapeutic use. Cushing Syndrome / drug therapy. Cushing Syndrome / etiology. Dopamine Agonists / therapeutic use. Female. Growth Hormone-Secreting Pituitary Adenoma / therapy. Human Growth Hormone / analogs & derivatives. Human Growth Hormone / blood. Human Growth Hormone / therapeutic use. Humans. Hypophysectomy. Incidental Findings. Male. Pregnancy. Pregnancy Complications, Neoplastic / therapy. Prolactinoma / therapy. Radiosurgery. Receptors, Somatotropin / antagonists & inhibitors. Somatostatin / analogs & derivatives. Somatostatin / therapeutic use. Thyrotropin / blood

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19758960.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Dopamine Agonists; 0 / Pituitary Hormones; 0 / Receptors, Somatotropin; 0 / pegvisomant; 12629-01-5 / Human Growth Hormone; 3A64E3G5ZO / Bromocriptine; 51110-01-1 / Somatostatin; 80Q9QWN15M / quinagolide; 9002-60-2 / Adrenocorticotropic Hormone; 9002-71-5 / Thyrotropin; 98H1T17066 / pasireotide
  • [Number-of-references] 28
  •  go-up   go-down






Advertisement